NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Immuno-Oncology Summit Europe 2022.
Sam Zhang will chair the section dedicated to translational studies on Tuesday, 24 May, where he will present the “promising early clinical efficacy of NT-I7 in combination with pembrolizumab in immune-cold tumors”.
“Most colorectal cancers (CRC) and pancreatic cancers (PaC) are Microsatellite Stable (MSS). Unfortunately, checkpoint inhibitors are only approved for Microsatellite Instable High (MSI-H) type, which is found in a low percentage of CRC and PaC. NT-I7, a long-acting IL-7, has shown promising early anti-tumor activity in MMS CRC or PaC when used in combination with pembrolizumab,” said Samuel Zhang, PhD, Chief Business Officer, NeoImmuneTech, Inc. “Responses, once occurred, are durable and continue to deepen over time. We look forward to continuing to see such responses, as our clinical program progress in 2022”.
Details of the session:
Cambridge Healthtech Institute holds its Sixth Annual Immuno-Oncology Summit Europe in London’s Canary Wharf. During three days, recent advances in the development of promising immuno-oncology treatments will be discussed.